Imbioray Bio

Imbioray is a clinical-stage biotechnology company specializing in the development of next-generation radiopharmaceuticals, with a primary focus on Targeted Alpha Therapy (TAT). The company leverages its proprietary platform to design and develop precision medicines that deliver alpha-emitting isotopes, such as Actinium-225 and Lead-212, directly to cancer cells. Imbioray's pipeline includes candidates targeting high-value oncology markers like PSMA, FAP, and GPC3. Headquartered in Suzhou, China, the company is backed by prominent life science investors and aims to address unmet needs in solid tumors. The lead program, IMB-101, is currently undergoing clinical evaluation for the treatment of metastatic castration-resistant prostate cancer.